As you said, market and technical research is incredibly important for stakeholders' consideration. If the idea is really that "grand," then the market research should reflect that. Business presentation is also a factor, having done extensive research is absolutely necessary for making a case as to why money should be put into it. A few things that could be done are specifically aligning the project with the company's mission statement, presenting a cost optimization strategy, and potentially breaking up the project in stages.

Aligning the project with the company's mission statement is a effective strategy in initializing the project and making sure the stakeholders are amenable to the concept of the project in general. Presenting the budget as a "cost optimization" strategy implies that the PM has done extensive research into places where the COGS could be cut down. This initiates a sense of trust that stakeholders may have in the PM as well as frame the project as having had extensive research into it's budget already. Finally, breaking the project into phases with different budgets could be more manageable with finances and resources that are dedicated to it at a time.

Mitigating financial challenges requires a multifaceted approach where the focus is not only on the business case presentation but also on developing strategic and innovative financial planning. Some ways to mitigate the obstacles mentioned can be through the use of pilot studies to gather preliminary data. By doing so, the project scope can be refined and may attract early-stage investors based on the results provided. Moreover, smaller and more manageable phases of investment should be focused on which would reduce upfront financial commitment and provide early indicators of the project's viability. 

Project charters, especially in front-end research and development, are difficult to secure, especially when financial models fail to win sponsor support. Based on the insightful viewpoints offered, solving these difficulties requires a diversified approach beyond business case presentations. Aligning the project with the company's mission statement emphasizes how it supports organizational goals and values. This pleases stakeholders and reinforces the project's strategic goals. Presenting the budget as a "cost optimization" approach highlights the PM's extensive cost-cutting and efficiency-boosting research. This method builds stakeholder trust and presents the project as a well-planned investment.

As suggested, splitting the project into manageable parts reduces financial risks and uncertainties. Iterative pilot studies can gather preliminary data and refine project scope depending on early-stage observations. This saves upfront costs and proves the project's feasibility and ROI. Focusing on smaller investment phases allows stakeholders to incrementally assess project viability and make adjustments and optimizations.

Strategic alignment, innovative financial planning, and phased implementation are needed to write a compelling project charter. These tactics help project managers overcome financial problems and gain the resources needed for successful R&D projects.

I think this question highlights how uncomfortable the reality is that if a project is technically feasible and can actually help the market in a specific clinical area, it does not immediately seem that the project has commercial viability. If the financial model seems too risky, then leadership will get nervous and not give the charter. It is important to bring into light how the project can help the company in more aspects than just through a financial lens. This means that the idea needs to be framed correctly for the charter to be given. 

One way to handle this is to reframe the conversation from cost to value over time. A high COGS looks scary when it is viewed by itself. However, if the downstream benefit is a reduction in costs for hospitals and new market access, then the long-term gains should be quantified better in the proposal. With lifecycle return metrics, the charter is more likely to be given. 

Another aspect to consider is how the product itself helps the company’s image and development. If the project strengthens the company’s portfolio in that specific therapeutic area, or if it creates intellectual property that protects future products, then the project is more likely to be seen in a positive light. Additionally, the project may lead to connections with key institutions or leaders, which would also be beneficial to the company. These are qualitative benefits that should be examined as well to increase the chances of getting a project to charter. 

Ultimately, I do not believe that many ideas are too grand if there is research to back up the idea. Do you think project charter decisions are more influenced by the objective financial modeling, or do you think the organization’s current status on risk and strategy plays a bigger role? When should a project that got rejected be brought back up?

An additional way to mitigate financial pushback in front-end R&D could be to rework the product architecture before assuming the business case is fixed. Rather than presenting a high-COGS device as the only option, teams should explore modular design, platform strategies, and/or minimum-viable-product pathways. Thus, these alternative options would not only provide a simpler configuration but also greatly shorten time-to-revenue and produce real-world data to support later iterations. An alternative approach could also be to proactively integrate reimbursement strategy and payer engagement into early development. For example, if a clinical trial is required, it can be framed as a reimbursement-enabling investment rather than as a costly regulatory necessity, which may induce flux in leadership's perspective.  

Leveraging organizational dimensions, such as portfolio balancing and transparency of opportunity costs, may also reduce the likelihood of a project being rejected. Sometimes projects are rejected because leadership cannot compare them with internal investments; thus, if R&D teams frame proposals within a portfolio framework rather than as a single cost burden, comparisons may be easier. This raises the question: should front-end teams be trained more extensively in corporate finance and portfolio strategy so they can frame innovation within a capital-allocation logic?